Quick Answer
Dermata Therapeutics, Inc. reported Stockholders Equity of $6.22 million for fiscal year 2025.
Dermata Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $6.22M | +298.7% |
| 2024 | $1.56M | -75.4% |
| 2023 | $6.36M | +5.5% |
| 2022 | $6.02M | -40.4% |
| 2021 | $10.11M | +418.0% |
| 2020 | -$3.18M | -1412.2% |
| 2019 | -$210.2K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.96M | -16.5% | -29.5% |
| June 30, 2025 | $5.61M | +69.2% | -23.1% |
| March 31, 2025 | $7.30M | +91.7% | +367.7% |
| December 31, 2024 | $1.56M | -75.4% | -67.1% |
| September 30, 2024 | $4.74M | -26.0% | +42.9% |
| June 30, 2024 | $3.32M | -58.7% | -12.9% |
| March 31, 2024 | $3.81M | -52.9% | -40.1% |
| December 31, 2023 | $6.36M | +5.5% | -0.8% |
- Dermata Therapeutics, Inc. showed an increase of +298.7% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Dermata Therapeutics, Inc.’s stockholders equity has grown by 3061.3% (from -$210.2 thousand to $6.22 million).
- The most recent figure is from Dermata Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: